{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(1)"],"submitter":["Sasaki M"],"pubmed_abstract":["<h4>Abstract</h4>The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex is divided into three subcomplexes: cBAF, PBAF, and ncBAF. Constituent genes (e.g., SMARCB1, SMARCA4, SMARCA2, and SS18) of the SWI/SNF complex often harbor genetic abnormalities in various cancers. Previously, we found that histone acetyltransferases CBP/p300 dual inhibitors could be promising treatments for SMARCB1-deficient cancers. We show that treatment with CBP/p300 dual inhibitors causes synthetic lethality in cBAF-deficient cancers such as SMARCA4/SMARCA2-deficient and SS18–SSX fusion cancers. Given the sensitivity to CBP/p300 dual inhibitors and their commonality with SWI/SNF subcomplexes containing each subunit, CBP/p300 dual inhibitors could be promising treatments for cancers harboring ab"],"journal":["Cancer research communications"],"pagination":["24-38"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11701801"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers."],"pmcid":["PMC11701801"],"pubmed_authors":["Ogiwara H","Sasaki M","Shimizu T","Yoshida H","Kato D"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers.","description":"<h4>Abstract</h4>The SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex is divided into three subcomplexes: cBAF, PBAF, and ncBAF. Constituent genes (e.g., SMARCB1, SMARCA4, SMARCA2, and SS18) of the SWI/SNF complex often harbor genetic abnormalities in various cancers. Previously, we found that histone acetyltransferases CBP/p300 dual inhibitors could be promising treatments for SMARCB1-deficient cancers. We show that treatment with CBP/p300 dual inhibitors causes synthetic lethality in cBAF-deficient cancers such as SMARCA4/SMARCA2-deficient and SS18–SSX fusion cancers. Given the sensitivity to CBP/p300 dual inhibitors and their commonality with SWI/SNF subcomplexes containing each subunit, CBP/p300 dual inhibitors could be promising treatments for cancers harboring ab","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-07-15T08:47:18.165Z","creation":"2026-07-02T03:08:44.514Z"},"accession":"S-EPMC11701801","cross_references":{"pubmed":["39625239"],"doi":["10.1158/2767-9764.CRC-24-0484"]}}